Previous Close | 88.65 |
Open | 88.75 |
Bid | 89.00 x 100 |
Ask | 89.30 x 100 |
Day's Range | 87.90 - 91.16 |
52 Week Range | 43.89 - 121.90 |
Volume | |
Avg. Volume | 662,228 |
Market Cap | 5.65B |
Beta (5Y Monthly) | 0.58 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.41 |
Earnings Date | Oct 24, 2024 - Oct 28, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 127.35 |
The average of price targets set by Wall Street analysts indicates a potential upside of 41.4% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.